Northpointe Bancshares, Inc.

NYSE:NPB

Banks - Regional

Financial Services
$14.79 +0.11%

+$0.02 today

Market cap
$511.47M
Beta
0.11
P/E (TTM)
3.1
EPS (TTM)
$5.85
Dividend yield
0.56%
52W Low $12.95High $19.48

Volume 0.33M

Average 0.15M

NPB EBITDA Margin

EBITDA as a percentage of revenue.

Northpointe Bancshares, Inc.NYSE: NPB

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 24.4%

EBITDA Margin was 24.4% in Q1 FY2026, up 1.4 pp from a year earlier. On a trailing-twelve-month basis it was 24.2%, up 3.7 pp year over year. Over 3 fiscal years it widened by 12.4 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 43.5% for the fiscal year ending Dec 2026, up from 24.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
24.4%-0.6 pp QoQ
Last fiscal yearDec 2025
24.1%+4.4 pp YoY
LTMMar 2026
24.2%+3.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.4 pp+26.1 pp+24.7 pp
1 year+4.4 pp+19.4 pp+15.0 pp
3 years+12.4 pp+33.1 pp+20.7 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
24.1%
Year-over-year change
+4.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NPB compares with its peers on the latest reported figures

  • NPB's LTM Mar 2026 EBITDA Margin of 24.2% is the highest of the 4 companies compared; the peer median is -37.5%.
  • Its year-over-year change of +3.7 pp is the 3rd highest of 4, against a peer median of +8.1 pp.
  • Over three fiscal years its change of +12.4 pp compares with a peer median of +167.8 pp.
NPB Competitors Peer median
EBITDA Margin for NPB and competitors
Company Period LTM level YoY 3-year change
NPBNorthpointe Bancshares, Inc.LTM Mar 202624.2% +3.7 pp+12.4 pp
LEGNLegend Biotech CorporationLTM Sep 20267.3% +27.5 pp+333.4 pp
ZLABZai Lab LimitedLTM Jun 2026-37.5% +8.1 pp+167.8 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-287.9% -44.6 pp+113.4 pp
ERASErasca, Inc.FY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding NPB) -37.5%+8.1 pp+167.8 pp

Competitors are the stored peer set for NPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.17M324.24M362.45M390.46M471.18M
Cost of Revenue1.14M68.9M164.68M202.99M231.56M
Gross Profit1.02M255.34M197.77M187.47M239.62M
Gross Margin47.3%78.7%54.6%48.0%50.9%
Research & Development29.88M0000
Selling, General & Admin22.17M159.88M104.29M77.79M93.62M
Operating Expenses52.05M221.65M153.08M114.59M129.23M
Depreciation & Amortization840.94K4.02M4.02M3.8M3.07M
EBITDA(56.67M)37.71M48.7M76.68M113.47M
EBITDA Margin-2613.5%11.6%13.4%19.6%24.1%
Operating Income(51.03M)33.69M44.69M72.88M110.39M
Operating Margin-2353.1%10.4%12.3%18.7%23.4%
Interest Income525.54K166.12M267.38M317.53M380.2M
Interest Expense066.69M166.16M203.32M229.47M
Other Income / Expenses(6.49M)0000
Income Before Tax(57.52M)33.69M44.69M72.88M110.39M
Pre-Tax Margin-2652.3%10.4%12.3%18.7%23.4%
Income Tax Expense(77.7K)10.46M10.93M17.72M26.98M
Net Income(57.44M)23.24M33.76M55.16M83.41M
Net Margin-2648.7%7.2%9.3%14.1%17.7%
EPS (Basic)(1.74)0.921.613.154.92
EPS (Diluted)(1.74)0.921.613.154.85
Weighted Avg Shares33.03M14.92M14.92M14.92M14.54M
Weighted Avg Shares (Diluted)33.03M14.92M14.92M14.92M14.72M

Northpointe Bancshares, Inc.

NYSE:NPB

Intrinsic Alpha fair value

Locked

Current Price

$14.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.